Merus N.V. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
740.80
1,728.40
1,458.20
1,473.50
13,992.00
36,869.50
Cost of Goods Sold (COGS) incl. D&A
7,761.30
9,374.00
-
-
-
-
Gross Income
7,020.40
7,645.60
-
-
-
-
SG&A Expense
5,009.10
8,292.90
22,626.40
25,459.10
53,581.40
66,652.30
EBIT
12,029.60
15,938.60
21,382.20
22,710.20
39,948.10
44,379.80
Unusual Expense
1,121.80
7,168.10
4,900.30
1,648.20
1,171.90
1,681.10
Non Operating Income/Expense
-
-
734.10
6,252.20
30,014.30
15,715.50
Interest Expense
73.00
51.70
216.20
21,730.10
12,278.70
-
Pretax Income
13,154.00
23,092.10
25,709.20
52,243.50
82,158.80
28,211.40
Income Tax
-
-
-
-
280.90
420
Consolidated Net Income
13,154.00
23,092.10
25,709.20
52,243.50
82,439.60
28,631.30
Net Income
13,154.00
23,092.10
25,709.20
52,243.50
82,439.60
28,631.30
Net Income After Extraordinaries
13,154.00
23,092.10
25,709.20
52,243.50
82,439.60
28,631.30
Net Income Available to Common
13,154.00
23,092.10
25,709.20
52,243.50
82,439.60
28,631.30
EPS (Basic)
0.81
1.42
1.59
3.95
4.30
1.28
Basic Shares Outstanding
16,232.10
16,232.10
16,232.10
13,236.60
19,196.40
22,286.70
EPS (Diluted)
0.81
1.42
1.58
3.95
4.29
1.28
Diluted Shares Outstanding
16,232.10
16,232.10
16,232.10
13,236.60
19,196.40
22,286.70
EBITDA
11,679.10
15,603.00
21,168.20
22,451.40
39,589.40
43,627.20
Other Operating Expense
-
-
-
1,534.30
-
13,844.40
Non-Operating Interest Income
70.40
66.30
55.40
97.30
1,254.30
2,134.20

About Merus

View Profile
Address
Yalelaan 62
Utrecht Utrecht 3584 CH
Netherlands
Employees -
Website http://www.merus.nl
Updated 07/08/2019
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.